Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases

Tanaka, Kuniya; Shimada, Hiroshi; Matsuo, Keitaro; Nagano, Yasuhiko; Endo, Itaru; Sekido, Hitoshi; Togo, Shinji

doi:10.1016/j.surg.2004.02.012

Cited by 202 publications

(162 citation statements)

References 27 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…Practicar la I N V E S T I G A C I Ó N cirugía colónica y hepática diferidamente o resecar las metástasis en forma simultánea a la cirugía colorrectal. La cirugía en 2 tiempos es la opción que se ha preferido en muchos centros, aunque recientemente han aparecido grupos que proponen realizar la cirugía en forma simultánea [26][27][28][29] . Esta serie presenta 32% de resecciones simultá-neas.…”

Section: Discussionunclassified

Resultados del tratamiento quirúrgico de las metástasis hepáticas por cáncer colorrectal

et al. 2009

View full text Add to dashboard Cite

Outcome of surgical treatment of liver metastasis from colorectal cancer 1 (1990-1997) and period 2 (1998-2007 (77% and 55%, respectively, p =0.04), without an increase in complications (35% and 34%, respectively; p =ns), but with a better five years survival (45% and 21%, respectively, p =0.04). Conclusions: Five years survival for excision of liver metastatic colorectal cancer in our center is similar to that reported abroad. During the second period there has been a trend toward more extensive resections which was associated with a better survival, without an increase in complications or mortality (Rev Méd Chile 2009; 137: 487-96).

show abstract

Section: Discussionunclassified

Resultados del tratamiento quirúrgico de las metástasis hepáticas por cáncer colorrectal

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Traditionally, a staged approach with initial resection of the primary disease followed by hepatic resection was recommended, but nowadays a simultaneous colon and liver resection is safe and efficient for CLM and LMNETs, since prognosis is not dependent on the time of resection [147][148][149][150] . Contraindications include the need for primary emergency surgery, a locally advanced colorectal tumour, or the need for major hepatectomy involving three or more segments.…”

Section: Techniquementioning

confidence: 99%

Metastatic lesions to the liver: Surgical indications and techniques

Tejedor¹,

Serrablo²

2013

JST

View full text Add to dashboard Cite

Background: Although there is an established agreement on the advantage of liver resection for metastatic colorectal and neuroendocrine tumours, the role of hepatic surgery in patients with liver metastases from non-colorectal and non-neuroendocrine carcinoma is not well defined. In recent years, despite the poor results, liver metastases suitable for surgery have been treated with resection. The results reported in recent studies support a developing trend toward surgery in this setting. Also, as there are no data that in fact suggest the utility of alternative treatments for these lesions, the role of surgery is reinforced. Methods:A systematic search of English and non-English literature using MEDLINE on the outcomes of patients after surgical treatment of liver metastases from different solid tumours was undertaken. A summary of current surgical techniques used to improve their resectability has been added.Results: All papers reporting median survival and 5-year survival have been selected and presented in tables for most of the primary tumours reviewed. Conclusions:Apart from patients with colorectal and neuroendocrine tumours, liver resection may offer a significative survival advantage in selected patients, mainly those with metastases coming from breast, gastrointestinal stromal tumours, testis, ovary and kidney.

show abstract

“…Even in the case of repeat hepatectomy, the operation itself was reported to be safe and to offer survival benefit [23]. In cases of recurrence, 70% were observed within 12 months after the initial liver operation, with 92% observed within 24 months [24], and for disease isolated to the liver, repeat hepatic resection led to favourable patient survival [25,26]. The criteria for the selection of patients for hepatic re-resection included the ability to achieve an R0 resection, the disease-free interval, solitary recurrences, and operative risk.…”

Section: The Role Of Surgical Proceduresmentioning

confidence: 99%

Strategies for Synchronous and Multiple Metastatic Liver Tumors Designed from Epithelial-Mesenchymal Transition Concept

Osada¹,

Imai²,

Sasaki³

et al. 2012

JCT

View full text Add to dashboard Cite

At some point in the natural course of colorectal cancer up to 50% of patients will develop metastasis to the liver and it is one of the most critical effects for patient prognosis. The incidence of synchronous liver metastasis has been detected at around 20% -25%, but the optimal timing of surgical resection remains controversial. Neoadjuvant chemotherapy has also been found to be beneficial not only for initially unresectable but also resectable synchronous metastases. Then, traditional surgical strategies of hepatic resection in accordance with past chemotherapeutic regimens have been used decreasingly over the past several years. This review will primarily discuss treatments in association with the recent developed chemotherapeutic regimens and surgical procedure from the clinical data and the concept for epithetlial-mesenchymal transition, which has recently been studied to elucidate mechanisms of the liver metastatic process.

show abstract

Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases

Cited by 202 publications

References 27 publications

Resultados del tratamiento quirúrgico de las metástasis hepáticas por cáncer colorrectal

Resultados del tratamiento quirúrgico de las metástasis hepáticas por cáncer colorrectal

Metastatic lesions to the liver: Surgical indications and techniques

Strategies for Synchronous and Multiple Metastatic Liver Tumors Designed from Epithelial-Mesenchymal Transition Concept

Contact Info

Product

Resources

About